Avexima: Nobazit

Main article: Drugs for coronavirus COVID-19

2022: Organization of production in IP "Esipovo"

On January 18, 2022, the Moscow Region Development Corporation announced that the Avexima pharmaceutical company was organizing the production of the Nobazit antiviral drug to combat COVID-19 as part of an investment project in the Esipovo IP near Moscow.

An additional agreement between Avexima and the Moscow Region Development Corporation on expanding cooperation within the framework of the investment project was signed in December 2021. This was reported by the Minister of Investment, Industry and Science of the Moscow Region Ekaterina Zinovieva.

{{quote 'At the end of 2021, Avexima and the Moscow Region Development Corporation signed an additional agreement to increase the area of ​ ​ the site for the project from 20 to 33 hectares, as well as to increase investments from 3 to 6.5 billion rubles. The number of jobs at the enterprise will also increase - from 1000 to 1450 people. The investor plans to produce drugs, including anti-tumor drugs and antibiotics. In addition, in connection with the growing spread of coronavirus infection, the company decided to additionally produce a drug against COVID-19 Nobazit, which will be used to treat a new omicron strain, "said Ekaterina Zinovieva, head of the Ministry of Investment, Industry and Science of the Moscow Region. }}

Interim results of clinical studies showed that the drug "Nobazit" fivefold reduces the likelihood of death from Covid-19 and doubles the risk of pulmonary failure. The drug is promising for treatment of a new omicron strain COVID-19 and available agent for prevention of severe consequences of ARVI and influenza. The medicine is relevant in anticipation of the season of colds and the next wave of pandemic predicted by virologists.

During the rapid spread of the pandemic, the emergence of various strains of coronavirus, it is very important to effectively develop research activities in the field of medicine, develop new drugs and expand pharmaceutical production. We are glad that on the territory of ISP "Esipovo" in the Moscow region there are localized enterprises that introduce knowledge-intensive pharmaceutical technologies, create highly skilled jobs and play an important social role. I am sure that the implementation of the Avexima project will expand the company's range of products for the treatment of dangerous diseases, strengthen synergies with other high-tech companies - residents of ISP Esipovo, provide the region with new scientific personnel, "said Vladimir Slipenkin, General Director of the Moscow Region Development Corporation.

The emergence of additional capacities equipped with European equipment and technologies will ensure the increased need of patients for the Nobazit antiviral drug, which is used in comprehensive therapy for Covid-19, said Elena Tkachenko, Director General of Avexima OJSC.